| DB ID | MyCo_2365 |
| Title | Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation |
| Year | 2020 |
| PMID | 31919585 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | Cystic fibrosis |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by Institute’s Ethics Committee (IEC- NK/2270/ Study/2062). |
| Site of Infection | Multiple organs |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | TGF-ß1 |
| Biomarker Full Name | Transforming Growth Factor-ß1 |
| Biomarker Type | Diagnostic |
| Biomolecule | Gene |
| Geographical Location | India |
| Cohort | The paediatric subjects (2 months to 18 years) diagnosed with CF were enrolled from Paediatric Pulmonology unit of PGIMER, Chandigarh (n = 35) with their informed consent. Out of these 35 patients, 26 were categorized in exacerbation phase and 9 were categorized in non-exacerbation phase. The sex- and age-matched healthy subjects were also enrolled in the study (n = 10).The blood sample was withdrawn at different time points: during exacerbation, nonexacerbation, before the start of antibiotic therapy and after antibiotic therapy (after 14 days of treatment).The exacerbation was defined according to the criteria by Eurocare CF working group which include “recent change in at least two of the following: increased cough, increased malaise, change in sputum volume or colour, increased dyspnoea, fatigue or lethargy, anorexia or weight loss, decrease in pulmonary function by 10% or more or radiographic changes”. The non-exacerbation phase included subjects whose sputum cultures were positive for bacteria but were asymptomatic and did not require antibiotic treatment. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cystic Fibrosis (CF) is a recessive genetic disorder which affects organs like lungs, pancreas, intestine etc. Although most of the morbidity and mortality is associated with the lung damage caused by recurrent infections and inflammation, there is a large variability in severity of pulmonary phenotype even among CF patients with homozygous ΔF508 mutation. The prediction of CF severity has been explored through genetic and environmental factors. Several studies have reported the role of Transforming Growth Factor β-1 (TGF-β1) as a modifier gene which modulates the phenotypic expression in CF. TGF-β1 is produced by alveolar macrophages and bronchial epithelial cells in lungs. This cytokine mediates its effects in CF through the inhibition of epithelial proliferation and induction of genes which promote fibrosis and inhibit metalloproteases. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA kit DRG International, USA |
| Assay Data | None |
| Validation Techniques used | ELISA, Amplification Refractory Mutation System (ARMS) PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
